(2008). AbESTT-II Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II) Stroke.
after acute ischaemic stroke (SITS-ISTR): an observational study.
(2009). Efficacy of a free radical scavenger, edaravone, on lacunar infarction (abstract).
(2008). EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurology.
for the ECASS Investigators. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke.
for the PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
(2008). Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol.
Shneider A; for the AXIS study group. AX200 (G-CSF) for the Treatment of Acute Ishcemic Stroke (AXIS)
Sonothrombolysis with transcranial color-coded sonography and recombinant tissue-type plasminogen activator in acute middle cerebral artery main stem occlusion: results from a randomized study.
(2008). The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet.
(2008). Thurman RJ; for the CLEAR Trial Investigators. The Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke. The CLEAR Stroke Trial. Stroke.
TNK Induces Faster MCA Recanalisation and leads to Better Short- and Long-term Clinical Outcome Than Native TPA. The TNK-TPA Reperfusion Stroke Study (abstract).
Treatment of Hyperglycaemia In Ischemic Stroke (THIS): a randomised pilot trial.
(2008). Wladyslaw MD; Frison, Lars PhD; Olsson, S Bertil MD; on behalf of the SPORTIF III, V Investigators. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V trials Stroke.